CompletedPhase 3

The Study of Atherosclerosis With Ramipril and Rosiglitazone

1,200 participantsStarted 2001-07

Plain-language summary

The purpose of this study is to determine if ramipril and/or rosiglitazone retard the progression of atherosclerosis as evaluated by serial carotid intermedial thickness measurements.

Who can participate

Age range

30 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * impaired glucose tolerance (FPG \< 7 mmol/L or 126 mg/dL \& 2hr PG between 7.8-11.0 mmol/l \[140-199 mg/dl\] after a 75 g OGTT * impaired glucose tolerance (FPG≥ 6.1 mmol/l \[110 mg/dl\]) and no diabetes (i.e. a FPG \< 7.0 mmol/l \[126 mg/dl\]) * a technically adequate baseline carotid ultrasound examination Exclusion Criteria: * current use of an ACE-inhibitor (ACE-I) or thiazolidinedione (TZD) * known hypersensitivity to ACE-I * prior use of anti-diabetic medications 9with the exception of during pregnancy) * use of systemic glucocorticoids or niacin * congestive heart failure or EF \< 40% * existing cardiovascular disease (previous MI, stroke, angina, uncontrolled hypertension) * diabetes * renal or hepatic disease * major illness * use of another experimental drug * pregnant or unwilling to use reliable contraception * major psychiatric disorder * diseases that affect glucose tolerance * unwillingness to be randomized or sign informed consent * known uncontrolled substance abuse * inability to communicate with research staff

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The change of the mean maximum carotid intimal medial thickness (IMT)evaluated across 12 segments involving the left and right common carotid, bifurcation and internal carotid arteries.

Trial details

NCT IDNCT00140647

SponsorGerstein, Hertzel, MD

Sponsor typeINDIV

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Atherosclerosis trials

Who can participate

Age range

30 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.